Genenta Science S.r.l

Genenta Science was founded in 2015 by Ospedale Raffaele Hospital (OSR), Milan, Pierluigi Paracchi, Luigi Naldini, and Bernhard Gentner. The company is a spin-off of the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), a world-leading cell and gene therapy research institution.

Genenta Science's product and project is Temferon™, a cell-based platform that harnesses the power of hematopoietic stem cells to deliver an immunotherapeutic payload within tumors, where it can direct the natural immune responses towards malignant cells. Temferon™ is not tumor type nor target antigen restricted and provides a sustained targeted expression of therapeutic payload(s) inside the tumor microenvironment. Genenta Science plans to expand its pipeline to other hard-to-treat cancer types in the future.

Genenta Science's vision is to provide durable and safe treatments for solid tumors, which are often resistant to conventional therapies such as chemotherapy, radiation, and immunotherapy. The company aims to develop Temferon™ as a one-time monotherapy, but also as a potential combination therapy with other approved therapeutics.

Genenta Science's market cap is $1.7B in May 2023. The company has also received several awards and recognitions, such as being selected as one of the 50 most innovative companies in Italy by Wired magazine in 2019.

Foundation: 2015

Headquarters: Milano, Italy

Website: https://www.genenta.com/